Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24125789 | 1.00 | CRBN (0.51) | CRBNDDB1POLBCDK9ADRA1D | |
| SCHEMBL25451460 | 0.90 | CRBN (0.52) | CRBNDDB1POLBIKZF1HDAC8 | |
| SCHEMBL29197004 | 0.90 | CRBN (0.48) | CRBNDDB1POLBADRA1DADRA1A | |
| SCHEMBL24880630 | 0.89 | CRBN (0.43) | CRBNDDB1CDK9IKZF1IKZF2 | |
| SCHEMBL29197001 | 0.88 | CRBN (0.48) | CRBNDDB1POLB | |
| SCHEMBL24881395 | 0.87 | CRBN (0.42) | CRBNDDB1POLBADRA1DADRA1A | |
| SCHEMBL24819375 | 0.86 | CRBN (0.53) | CRBNDDB1POLBIKZF1HDAC8 | |
| SCHEMBL29094549 | 0.86 | CRBN (0.40) | CRBNDDB1POLBADRA1DADRA1A | |
| SCHEMBL31443818 | 0.86 | CRBN (0.47) | CRBNDDB1IKZF1HDAC8 | |
| SCHEMBL30796810 | 0.86 | CRBN (0.52) | CRBNDDB1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022194269-A1 | NOVEL EGFR DEGRADATION AGENT | 上海齐鲁制药研究中心有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | CRBN 193/4885DDB1 433/4885POLB 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.